Cargando…

Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer

Concurrent chemoradiotherapy (CCRT) is a common treatment for advanced oral cancer, and its efficacy has been reported in many reviews. We have performed concurrent CCRT with intravenous cisplatin and docetaxel in patients with advanced oral cancer. The purpose of this report was to evaluate this tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Kotaro, Hayashi, Yasushi, Watanabe, Kazuyo, Yoshimi, Ryoko, Hibi, Hideharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728193/
https://www.ncbi.nlm.nih.gov/pubmed/31579331
http://dx.doi.org/10.18999/nagjms.81.3.407
_version_ 1783449390386511872
author Sato, Kotaro
Hayashi, Yasushi
Watanabe, Kazuyo
Yoshimi, Ryoko
Hibi, Hideharu
author_facet Sato, Kotaro
Hayashi, Yasushi
Watanabe, Kazuyo
Yoshimi, Ryoko
Hibi, Hideharu
author_sort Sato, Kotaro
collection PubMed
description Concurrent chemoradiotherapy (CCRT) is a common treatment for advanced oral cancer, and its efficacy has been reported in many reviews. We have performed concurrent CCRT with intravenous cisplatin and docetaxel in patients with advanced oral cancer. The purpose of this report was to evaluate this treatment and to compare the outcome of this treatment with that of standard CCRT treatments for advanced head and neck cancer using intravenous administration. The patients were treated for primary advanced oral squamous cell carcinoma in our department between February 2003 and November 2015. In all, 17 patients (14 men, 3 women) with stage III (2 patients) stage IVA (10 patients), and stage IVB (5 patients) oral cancer were treated. The patient ages ranged from 44 to 87 years (average age: 65.4 years). The follow-up duration ranged from 5 to 117 months (average follow-up duration: 41 months, median follow-up duration: 39 months). The primary cancer sites were the maxillary gingiva (7 cases), mandible gingiva (3 cases), buccal mucosa (3 cases), tongue (3 cases), and floor of the mouth (1 case). The 3-year and 5-year survival rates were 52.9% and 33.0%, respectively, and both the 3-year and 5-year locoregional control rates were 50.9% as determined by the Kaplan-Meier method. The response rate was 94% (CR: 8 cases: 47% and PR: 8 cases: 47%). The incidences of toxicity greater than grade 3 included dermatitis and stomatitis in 9 cases each (52.9%), anemia in 3 cases (18.7%) and liver dysfunction in 1 case (6.2%). We found that the results of this therapy were equivalent to those of standard CCRT treatments for advanced head and neck cancer using intravenous administration, and the incidences of toxicity were lower than those of standard treatments. These findings suggested that this treatment is safe and useful for advanced oral cancer.
format Online
Article
Text
id pubmed-6728193
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nagoya University
record_format MEDLINE/PubMed
spelling pubmed-67281932019-10-02 Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer Sato, Kotaro Hayashi, Yasushi Watanabe, Kazuyo Yoshimi, Ryoko Hibi, Hideharu Nagoya J Med Sci Original Paper Concurrent chemoradiotherapy (CCRT) is a common treatment for advanced oral cancer, and its efficacy has been reported in many reviews. We have performed concurrent CCRT with intravenous cisplatin and docetaxel in patients with advanced oral cancer. The purpose of this report was to evaluate this treatment and to compare the outcome of this treatment with that of standard CCRT treatments for advanced head and neck cancer using intravenous administration. The patients were treated for primary advanced oral squamous cell carcinoma in our department between February 2003 and November 2015. In all, 17 patients (14 men, 3 women) with stage III (2 patients) stage IVA (10 patients), and stage IVB (5 patients) oral cancer were treated. The patient ages ranged from 44 to 87 years (average age: 65.4 years). The follow-up duration ranged from 5 to 117 months (average follow-up duration: 41 months, median follow-up duration: 39 months). The primary cancer sites were the maxillary gingiva (7 cases), mandible gingiva (3 cases), buccal mucosa (3 cases), tongue (3 cases), and floor of the mouth (1 case). The 3-year and 5-year survival rates were 52.9% and 33.0%, respectively, and both the 3-year and 5-year locoregional control rates were 50.9% as determined by the Kaplan-Meier method. The response rate was 94% (CR: 8 cases: 47% and PR: 8 cases: 47%). The incidences of toxicity greater than grade 3 included dermatitis and stomatitis in 9 cases each (52.9%), anemia in 3 cases (18.7%) and liver dysfunction in 1 case (6.2%). We found that the results of this therapy were equivalent to those of standard CCRT treatments for advanced head and neck cancer using intravenous administration, and the incidences of toxicity were lower than those of standard treatments. These findings suggested that this treatment is safe and useful for advanced oral cancer. Nagoya University 2019-08 /pmc/articles/PMC6728193/ /pubmed/31579331 http://dx.doi.org/10.18999/nagjms.81.3.407 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Paper
Sato, Kotaro
Hayashi, Yasushi
Watanabe, Kazuyo
Yoshimi, Ryoko
Hibi, Hideharu
Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title_full Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title_fullStr Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title_full_unstemmed Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title_short Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
title_sort concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728193/
https://www.ncbi.nlm.nih.gov/pubmed/31579331
http://dx.doi.org/10.18999/nagjms.81.3.407
work_keys_str_mv AT satokotaro concurrentchemoradiotherapywithintravenouscisplatinanddocetaxelforadvancedoralcancer
AT hayashiyasushi concurrentchemoradiotherapywithintravenouscisplatinanddocetaxelforadvancedoralcancer
AT watanabekazuyo concurrentchemoradiotherapywithintravenouscisplatinanddocetaxelforadvancedoralcancer
AT yoshimiryoko concurrentchemoradiotherapywithintravenouscisplatinanddocetaxelforadvancedoralcancer
AT hibihideharu concurrentchemoradiotherapywithintravenouscisplatinanddocetaxelforadvancedoralcancer